ClinicalTrials.gg
CompletedNCT05683340Updated Mar 13, 2025Results posted

A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

A Phase 3 interventional study of 180mg of ETC-1002(bempedoic acid) and Placebo in Hyper-low-density Lipoprotein (LDL) Cholesterolemia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to confirm the superiority of ETC-1002 after 12 weeks of administration at 180 mg/day to placebo in patients with hyper-LDL cholesterolemia who have inadequate control of low-density lipoprotein cholesterol (LDL C).

02

Conditions studied

  • Hyper-low-density Lipoprotein (LDL) Cholesterolemia
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with inadequate response to statins or statin intolerance as defined below [Inadequate response to statins] Patients with hyper-LDL cholesterolemia who have been taking statins[and other lipid-modifying therapies(LMTs) if needed] and cannot achieve the lipid management goals of LDL-C [Statin intolerance] Patients with hyper-LDL cholesterolemia for whom safety problems have occurred while taking at least one type of statin, and who experienced resolution of the problems after discontinuation or dose reduction, and who cannot achieve the lipid management goals of LDL-C. Patients must be on the lowest or under the dosage of the approved dose of statin and/or on stable LMT(s).
  • Patients with fasting TG levels of \<400 mg/dL at screening
  • Other protocol specific inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or breast-feeding or who have a positive pregnancy test (urine) result at screening or baseline visits
  • Patients with homozygous familial hypercholesterolemia (HoFH)
  • Patients who currently have or who have had within the past 3 months prior to screening any cardiovascular diseases, or those who have developed any cardiovascular diseases during the screening or before baseline visit
  • Uncontrolled hypertension, defined as sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening
  • Patients with uncontrolled and serious hematologic or coagulation disorders or with of \<10.0 g/dL at screening
  • Patients with uncontrolled diabetes with of ≥9% at screening
  • Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of >1.5 × at screening
  • Patients with liver disease or dysfunction, including:

    • Positive serology for surface antigen (HBsAg) or a positive virus (HCV) antibody test at screening
    • (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN or total of ≥2 × ULN at screening
  • Patients with creatine kinase (CK) of >3 × ULN at screening
  • Patients with a history or current renal dysfunction, nephritic syndrome, or nephritis, and with estimated (eGFR) of ≤30 mL/min/1.73 m2 at screening
  • Other protocol specific exclusion criteria may apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    ETC-1002 180mg

    Drug: 180mg of ETC-1002(bempedoic acid)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change in LDL-C From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1.

    Time frame: Baseline, week12

Secondary outcomes

  1. Percent Change in Non-HDL Cholesterol From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  2. Percent Change in Total Cholesterol From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  3. Percent Change in Apolipoprotein B From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  4. Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  5. Percent Change in Hemoglobin A1c From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  6. Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12

    The proportion of subjects whose LDL-C value achieves the lipid management goal at Week 12.

    Time frame: Baseline, week12

07

Results

Posted Mar 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneETC-1002 180 mgPlacebo
Started4848
Completed4645
Not completed23
Withdrew: Adverse event11
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryPercent Change in LDL-C From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in LDL-C From Baseline to Week 12
Percent ChangeETC-1002 180 mgPlacebo
Percent Change in LDL-C From Baseline to Week 12-25.25 ± 1.864-3.46 ± 1.901
Statistical analysis
  • ETC-1002 180 mg vs Placebo · MMRM · p = 0.001 · Least squares mean difference: -21.78 · 95% CI -26.71 to -16.85The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryPercent Change in Non-HDL Cholesterol From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Non-HDL Cholesterol From Baseline to Week 12
Percent ChangeETC-1002 180 mgPlacebo
Percent Change in Non-HDL Cholesterol From Baseline to Week 12-20.33 ± 1.704-2.76 ± 1.720
SecondaryPercent Change in Total Cholesterol From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Total Cholesterol From Baseline to Week 12
Percent ChangeETC-1002 180 mgPlacebo
Percent Change in Total Cholesterol From Baseline to Week 12-16.36 ± 1.405-2.23 ± 1.409
SecondaryPercent Change in Apolipoprotein B From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Apolipoprotein B From Baseline to Week 12
Percent ChangeETC-1002 180 mgPlacebo
Percent Change in Apolipoprotein B From Baseline to Week 12-18.10 ± 1.762-0.67 ± 1.799
SecondaryPercent Change in High Sensitivity C Reactive Protein From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12
Percent ChangeETC-1002 180 mgPlacebo
Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 1215.40 ± 65.246119.60 ± 66.542
SecondaryPercent Change in Hemoglobin A1c From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Hemoglobin A1c From Baseline to Week 12
Percent ChangeETC-1002 180 mgPlacebo
Percent Change in Hemoglobin A1c From Baseline to Week 12-0.87 ± 0.5900.16 ± 0.594
SecondaryProportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12

The proportion of subjects whose LDL-C value achieves the lipid management goal at Week 12.

Time frame:
Baseline, week12
Reported as:
Count of participants · Participants
Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12
ParticipantsETC-1002 180 mgPlacebo
Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12304

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 28 (+7) days after the last dose of study medication, up to 21 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETC-1002 180 mg0/48 (0%)0/48 (0%)13/48 (27.1%)
Placebo0/48 (0%)0/48 (0%)6/48 (12.5%)
Most frequent other events
Most frequent other events
EventETC-1002 180 mgPlacebo
NasopharyngitisInfections and infestations7/485/48
ArthralgiaMusculoskeletal and connective tissue disorders3/480/48
Back painMusculoskeletal and connective tissue disorders3/481/48

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ETC-1002 180 mgPlaceboTotal
<=18 years000
Between 18 and 65 years202545
>=65 years282351
Age, Continuous
Age, Continuous(years)ETC-1002 180 mgPlaceboTotal
Mean64.6 ± 13.0263.9 ± 12.9864.2 ± 12.93
Sex: Female, Male
Sex: Female, Male(Participants)ETC-1002 180 mgPlaceboTotal
Female282351
Male202545
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ETC-1002 180 mgPlaceboTotal
Japanese484896
Region of Enrollment
Region of Enrollment(participants)ETC-1002 180 mgPlaceboTotal
Japan484896
08

Study locations

1 site
  • Rinku General Medical Center
    Izumisano-shi, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: "Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Feb 2024, 12 months.

Results were first posted in Mar 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 13, 2023
StartActual
Feb 13, 2023
Primary completionActual
Feb 20, 2024
CompletionActual
Mar 12, 2024
Results first posted
Mar 13, 2025
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05683340
Responsible party
Sponsor
First posted
Jan 13, 2023
Start date
Feb 13, 2023
Primary completion
Feb 20, 2024
Completion
Mar 12, 2024
Results posted
Mar 13, 2025
Last update
Mar 13, 2025

Study contacts

Takehisa Matsumaru
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion